MAPT and Alzheimer disease: We have used a new TAOK inhibitor to reduce tau phosphorylation on sites associated with neurodegeneration in human tauopathies and examined two new phosphorylation sites on tau (T123 and T427) that are targeted by TAOKs and detected in AD and FTLD brain.